After 16 weeks of therapy, significant improvements were observed in both PASI and DLQI scores (p < 0.001), reinforcing the efficacy of IL-17 and IL-23 inhibitors [3,30,31] and supporting the critical role of the IL-23/Th17 axis in managing psoriasis lesions and improving QoL. This evidence concerns the gene IL17A and psoriasis.